Thrombosis Research
Volume 125 , Pages S4-S6 , April 2010

History of rFVIIa therapy

  • Ulla Hedner

      Affiliations

    • Corresponding Author InformationRegementsgatan 23, 21753 Malmo, Sweden.

References 

  1. Nilsson IM, Hedner U, Björlin G. Suppression of factor IX antibody in haemophilia B by factor IX and cyclophosphamide. Ann Intern Med. 1973;78:91–95
  2. Nilsson IM, Hedner U, Holmberg L. Suppression of factor VIII antibody by combined factor VIII and cyclophosphamide. Acta Med Scan. 1974;195:65–72
  3. Sjamsoedin LJM, Heijnen L, Mauser-Bunschoten EP, van Geijlswijk JL, van Houwelingen H, van Asten P, et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. N Engl J Med. 1981;305:717–721
  4. Lusher JM, Blatt PM, Penner JA, Aledort LM, Levine PH, White GC, et al. Autoplex versus Proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood. 1983;62:1135–1138
  5. Young G, Shafer FE, Rojas P, Seremetis S. Single 270ug/kg-dose rFVIIa vs. standard 90ug/kg-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia. 2008;14:287–294
  6. Blatt PM, Lundblad RL, Kingdon HS, McLean G, Roberts HR. Thrombogenic materials in prothrombin complex concentrates. Ann Intern Med. 1974;81:766–770
  7. Kingdon HS, Lundblad RL, Veltkamp JJ, Aronson DL. Potentially thrombogenic materials in factor IX concentrates. Thromb Diath Haemorrh. 1975;33:617–631
  8. Hedner U, Nilsson IM, Bergentz S-E. Various prothrombin complex concentrates and their effect on coagulation and fibrinolysis in vivo. Thomb Haemost. 1976;35:386–395
  9. Hedner U, Nilsson IM, Bergentz S-E. Studies on thrombogenic activities in two prothrombin complex concentrates. Thromb Haemost. 1979;42:1022–1032
  10. Østerud B, Miller-Andersson M, Abildgaard U, Prydz H. The effect of antithrombin III on the activity of the coagulation factors VII, IX and X. Thromb Haemost. 1976;35:295–304
  11. Kurczynski EM, Penner JA. Activated prothrombin concentrate for patients with factor VIII inhibitors. N Engl J Med. 1974;291:164–167
  12. Penner JA, Kelly PE. Management of patients with factor VIII or IX inhibitors. Sem Thromb Haemost. 1975;1:386–399
  13. Seligsohn U, Kasper CK, Østerud B, Rapaport SI. Activated factor VII: presence in factor IX concentrates and persistence in the circulation after infusion. Blood. 1979;53:828–837
  14. Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest. 1983;71:1837–1841
  15. Hedner U, Schulman S, Alberts KA, Blombäck M, Johnsson H, Glazer S, et al. Successful use of rFVIIa in a patient with hemophilia A subjected to synovectomy. Lancet. 1988;II:1193
  16. Macik BG, Lindley CM, Lusher J, Sawyer WT, Bloom AL, Harrison JF, et al. Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a Phase I study. Blood Coagul Fibrinolysis. 1993;4:521–527
  17. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998;80:773–778
  18. Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thomb Haemost. 1998;80:912–918
  19. Lusher J, Ingerslev J, Roberts H, Hedner U. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis. 1998;9:119–128
  20. Kjalke M, Ezban M, Monroe DM, Hoffman M, Roberts HR, Hedner U. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol. 2001;114:114–120
  21. Kjalke M, Monroe DM, Hoffman M, Oliver JA, Ezban M, Roberts HR. Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation. Thromb Haemost. 1998;80:578–584
  22. Sørensen BB, Persson E, Freskgård P-O, Kjalke M, Ezban M, Williams T, et al. Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor. J Biol Chem. 1997;272:11863–11868
  23. Hedner U. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies. Thromb Haemost. 2008;100:557–562

PII: S0049-3848(10)00074-5

doi: 10.1016/j.thromres.2010.01.021

Thrombosis Research
Volume 125 , Pages S4-S6 , April 2010

Article Tools